NCT04126603View on ClinicalTrials.gov

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

October 25, 2023

Study Completion Date

May 14, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide

0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks

DRUG

Placebos

Placebo injection

Trial Locations (2)

20037

The GW Medical Faculty Associates, Washington D.C.

20422

Washington VA Medical Center, Washington D.C.

All Listed Sponsors
lead

Sabyasachi Sen

OTHER

NCT04126603 - Impact of Semaglutide on CD34+ EPC and Fat Derived MSC | Biotech Hunter | Biotech Hunter